A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples